StreetAlpha.app
Home › Stocks › VERA

Vera Therapeutics, Inc. (VERA)

Healthcare
$26.20
▼ −2.86%
LAST CLOSE · NOV 17

Vera Therapeutics develops drug candidates for serious immune system diseases, led by atacicept for IgA nephropathy, a kidney disease. It last closed at $26.20 on Nov 17, down 2.86% on the day. The average 12-month price target from 5 analysts is $57.40 (+119.1% from the last close), with a high of $83.00 and a low of $29.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in VERA, 75% of them bullish and 25% bearish.

AI Auto Pilots
Is VERA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$415.3M
EPS (diluted)
−$5.90
Free cash flow
−$376.0M
Valuation
Market cap
$1.9B
72.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.3M
At Sep 30
Debt
$75.4M
At Sep 30
Shareholder equity
$333.2M
Shares outstanding
72.3M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$32.6M−$32.6MFY2021FY2022: −$89.1M−$89.1MFY2022FY2023: −$96.0M−$96.0MFY2023FY2024: −$152.1M−$152.1MFY2024FY2025: −$299.6M−$299.6MFY2025

From VERA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
5firms
3 Buy2 Hold0 Sell
Each firm's latest rating on VERA in the past 90 days
Average 12-month target
$57.40
▲ 119.1% upside

Based on 5 analysts who set a price target on VERA in the past 90 days. The average target is $57.40, with a high of $83.00 and a low of $29.00, compared with the last close of $26.20.

Low $29.00Avg $57.40High $83.00
Blue marker: last close $26.20
Highest target$83.00
Average target$57.40
Lowest target$29.00
Latest rating changes
WedbushTarget lowered
Nov 6Hold$34 → $29
GuggenheimTarget lowered
Nov 6Buy$76 → $66
HC Wainwright & Co.Target lowered
Nov 6Buy$90 → $75
Leerink PartnersInitiated
Oct 12Hold$34
JP MorganMaintained
Sep 8Buy$83
DateFirmActionRatingPrice target
Nov 6WedbushTarget loweredHold$34 → $29
Nov 6GuggenheimTarget loweredBuy$76 → $66
Nov 6HC Wainwright & Co.Target loweredBuy$90 → $75
Oct 12Leerink PartnersInitiatedHold$34
Sep 8JP MorganMaintainedBuy$83
Loading…

Technical Analysis

VERA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 13% below its 20 day and 17% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $25.82, and the nearest resistance the Pivot at $26.32.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.2%/day
Key levels
$56.0552 week high+113.9%
$35.97200 day average+37.3%
$33.24100 day average+26.9%
$31.84Swing high (Oct 22)+21.5%
$30.7550 day average+17.4%
$29.6620 day average+13.2%
$26.81Pivot R1+2.3%
$26.32Pivot+0.5%
$26.20Last close
$25.8252 week low−1.5%
$25.70Pivot S1−1.9%
Indicators
RSI (14)35.58Weak, oversold below 30Neutral
MACD-0.73Below its signal lineBearish
Stochastic4.2Near the bottom of its rangeOversold
ADX (14)13.9No clear trend
Williams %R-94.5Oversold below −80, overbought above −20Oversold
CCI (20)-206.2Oversold below −100, overbought above 100Oversold
Rate of change−14.7%Change over 10 sessionsBearish
ATR (14)$1.61Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERA

What happened before

See how VERA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 1 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow VERA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VERA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
4
Bullish
3
75%
Bearish
1
25%
Date span
Aug 25 – Oct 6
Loading…

See today’s whale options flow across the market →

VERA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲128 buying vs 96 selling
  • ▲Held by funds +9.6 pts
  • ▲Funds holding +3
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding224221+1.4%
In funds' top 10137+85.7%
Held by funds117.4%107.8%+9.6 pts
New / increased39 / 8928 / 98+1.6%
Reduced / sold out59 / 3766 / 37−6.8%
Put/call ratio3.380.55+517.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VERA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERA is in one of them and how their past VERA trades turned out.

VERA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VERA in an article yet. Here's the latest on the wider market.

About Vera Therapeutics

Vera Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for serious immune system diseases, with a focus on kidney conditions. Its lead candidate, atacicept, is being studied for IgA nephropathy, a kidney disease, and other autoimmune kidney disorders, and is designed to be given at home by autoinjector. The company also holds rights to MAU868, which is being studied for BK viremia in kidney transplant patients, and to VT109, a preclinical candidate. Its target customers are patients with these conditions and the doctors who treat them.

Headquarters
Brisbane, CA